Press Releases

Press Releases

Press Releases

Date Title and Summary Additional Formats
Nov 29, 2016
Genomic Health Announces Presentation of Multiple Oncotype DX® Studies at the 2016 CTRC-AACR San Antonio Breast Cancer Symposium, Reinforcing Value of Genomics in Precision Medicine
REDWOOD CITY, Calif. , Nov. 29, 2016 /PRNewswire/ --  Genomic Health, Inc. ( NASDAQ : GHDX) today announced that it will present seven Oncotype DX ® studies at the 39 th CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), which is being held December 6-10, 2016 .
Nov 03, 2016
Genomic Health to Present at the Credit Suisse 25th Annual Healthcare Conference
REDWOOD CITY, Calif. , Nov. 3, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Brad Cole , chief operating officer and chief financial officer, will present at the Credit Suisse 25 th Annual Healthcare Conference in Scottsdale, Arizona on Tuesday, November 8, 2016 at
Nov 01, 2016
Genomic Health Reports Third Consecutive Quarter of Double-Digit Revenue Growth in Announcement of Third Quarter 2016 Financial Results
12% Increase in Revenue; 8% Increase in Tests Delivered
18% Constant Currency Increase in International Revenue and 15% Growth in International Tests Delivered
45% Improvement in Year-to-Date Operating Loss
Oncotype DX® Genomic Prostate Score™ Now Validated as Only Test to Measure All Four Critical Features of Tumor Aggressiveness
Conference Call Today at 4:30 p.m. ET
Nov 01, 2016
Genomic Health Announces Positive Topline Clinical Validation Study Results Demonstrating Oncotype DX® Prostate Cancer Test Predicts Risk of Metastasis and Mortality
Oncotype DX® Genomic Prostate Score™ Becomes Only Test Validated to Measure All Four Critical Features of Tumor Aggressiveness
Oct 26, 2016
Comprehensive Economic Analysis Published in Reviews in Urology Demonstrates Oncotype DX® Prostate Cancer Test Leads to Substantial Cost Savings and Increase in Active Surveillance
Unique Prospective Study Provides Real-world Evidence Demonstrating Use of Oncotype DX® Genomic Prostate Score™ Saves Over $2,000 per Patient by Optimizing Care and Healthcare Spending
Oct 25, 2016
Genomic Health to Announce Third Quarter 2016 Financial Results and Host Conference Call on Tuesday, November 1, 2016
REDWOOD CITY, Calif. , Oct. 25, 2016 /PRNewswire/ --  Genomic Health, Inc.  (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Tuesday, November 1 at 4:30 p.m. Eastern Time to discuss its third quarter 2016 financial results. The call and webcast will follow
Oct 11, 2016
Genomic Health Presents Robust Analytical Validation Study Results of Oncotype SEQ™ Liquid Biopsy Mutation Panel
Data Presented for First Time at ESMO 2016 Congress Highlight Company's Commitment to Delivering Rigorous, Clinically Actionable Liquid-based Tests for Late-stage Cancer Patients
Oct 10, 2016
Multiple Oncotype DX® Presentations at ESMO 2016 Congress Reinforce Its Unique Clinical Utility with Prospective Outcomes Results in Over 63,000 Breast Cancer Patients
Two Large International Studies Underscore Ability of Oncotype DX to Identify Patients with Node-positive Breast Cancer Who Can Forego Chemotherapy and Its Side Effects
Studies across Four Countries Demonstrate Oncotype DX Results Significantly Change Treatment Decisions and Reduce Chemotherapy Use
Sep 28, 2016
Genomic Health Reinforces Global Leadership in Genomic-based Diagnostics with Presentation of Nine Personalized Medicine Studies Conducted in Six Countries at ESMO 2016 Congress
Broad Range of Presentations Includes Oncotype SEQ™ Liquid Biopsy Analytical Validation, New Outcomes Data in Invasive Breast Cancer and Studies in Node-positive Disease
Aug 31, 2016
Genomic Health to Present at the 2016 Wells Fargo Healthcare Conference
REDWOOD CITY, Calif. , Aug. 31, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Kim Popovits , Chairman of the Board, Chief Executive Officer and President, will present at the 2016 Wells Fargo Healthcare Conference at the Westin Boston Waterfront Hotel in Boston on